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Diabetic polyneuropathy (DPN) occurs more frequently in type 1 diabetes resulting in a more severe DPN. The diﬀerences in
D P Nb e t w e e nt h et w ot y p e so fd i a b e t e sa r ed u et od i ﬀerences in the availability of insulin and C-peptide. Insulin and C-peptide
provide gene regulatory eﬀects on neurotrophic factors with eﬀects on axonal cytoskeletal proteins and nerve ﬁber integrity. A
signiﬁcant abnormality in type 1 DPN is nodal degeneration. In the type 1 BB/Wor-rat, C-peptide replacement corrects metabolic
abnormalities ameliorating the acute nerve conduction defect. It corrects abnormalities of neurotrophic factors and the expression
of neuroskeletal proteins with improvements of axonal size and function. C-peptide corrects the expression of nodal adhesive
molecules with prevention and repair of the functionally signiﬁcant nodal degeneration. Cognitive dysfunction is a recognized
complication of type 1 diabetes, and is associated with impaired neurotrophic support and apoptotic neuronal loss. C-peptide
prevents hippocampal apoptosis and cognitive deﬁcits. It is therefore clear that substitution of C-peptide in type 1 diabetes has a
multitude of eﬀects on DPN and cognitive dysfunction. Here the eﬀects of C-peptide replenishment will be extensively described
as they pertain to DPN and diabetic encephalopathy, underpinning its beneﬁcial eﬀects on neurological complications in type 1
diabetes.
Copyright © 2008 Anders A. F. Sima et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Diabetes is an increasingly common metabolic disorder that
aﬀects the nervous system in a variety of ways. It impacts on
the peripheral nervous system (PNS) in a progressive fashion
resulting in diabetic polyneuropathies (DPNs), which as a
group is the most common chronic diabetic complication
[1]. It also aﬀects the central nervous system (CNS) resulting
in progressive cognitive impairment and is associated with
an increased risk for the development of Alzheimer’s disease
[2, 3]. The mechanisms underlying these complications are
several and are not necessarily the same in type 1 and type
2 diabetes [2, 4–6]. Historically, hyperglycemia, which is a
common clinical attribute of both types of diabetes, has
been regarded as the major underlying factor initiating the
complications. However, this does not explain diﬀerences in
the neurological complications in the two types of diabetes,
nor does it explain the only partial beneﬁts in curbing the
progression or preventing the complications in trials aimed
at optimal hyperglycemic control, such as the DCCT and
UKPDStrials[7,8].Downstreameﬀectsofhyperglycemiaon
the polyol pathway and oxidative stress have been the targets
for numerous clinical trials with marginal eﬀects at best
[9–11]. These data strongly suggest that factors other than
hyperglycemia are involved in the initiation and progression
of DPN. Such factors may diﬀer in the two types of diabetes
as suggested by epidemiological studies. The prevalence of
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diabetes, whereas in type 1 diabetes it is close to 100% after
15-years disease duration [12–14], suggesting a more rapid
progression of DPN in type 1 diabetic subjects.
DPN involves both somatic and autonomic peripheral
nerves and is characterized as a progressive dying back
axonopathy. The structural pathology, however, diﬀers in the
two types of diabetes in that the axonopathy is more severe
in type 1 DPN and is in type 2 DPN associated with a greater
frequency of primary segmental demyelination. Type 1 DPN
is also characterized by progressive nodal and paranodal2 Experimental Diabetes Research
degeneration with signiﬁcant impact on nerve function,
abnormalities which do not occur in type 2 diabetes [4, 5,
15].
One factor that diﬀers between type 1 and type 2
diabetes and is likely the explanation for some of the
diﬀerences in DPN is the degree of perturbed insulin
signaling due to insulin deﬁciency in type 1 diabetes and
insulin resistance associated with hyperinsulinemia in type
2 diabetes. Insulin signaling exerts besides its hypoglycemic
eﬀect a multitude of metabolic and molecular eﬀects, which
are not commonly recognized. Pertaining to DPN, insulin
signaling has prominent eﬀects on Na+/K+-ATPase and NO
activities important for the metabolically induced acute
nerve dysfunction. It transduces strong neurotrophic eﬀects
on its own and possesses generegulatory functions on other
neurotrophic factors such as IGF-1, NGF, and NT-3 as well
as their receptors. Furthermore, it is an important regulator
of postranslational modiﬁcations of neuroskeletal and cell
adhesive proteins, and besides that it possesses a strong
antiapoptoticeﬀect.Consideringtheseeﬀects,itisnottotally
surprising that strict hyperglycemic control alone will not
provide total protection against DPN [7, 8], or CNS for that
matter, in diabetic subjects and that mechanistic, functional,
and structural diﬀerences exist between the neurological
complications occurring in the two types of diabetes [16].
Insulin is secreted from pancreatic beta cells in response
to glucose. Simultaneously, proinsulin C-peptide is secreted
in equimolar quantities. Insulin’s half-life in the circulation
is short whereas that of C-peptide is substantially longer
[17, 18]. C-peptide was initially believed to be a waste
product of insulin synthesis until the molecular bases for its
intriguinginsulin-like eﬀects were delineated [19, 20].
In this review, we will brieﬂy describe recent data
pertaining to the interaction between insulin and C-peptide,
outline the pathogenetic mechanisms underlying type 1
DPN, and contrast these to those of type 2 DPN. We will
describe the eﬀects of C-peptide on somatic and small ﬁber
neuropathy and brieﬂy summarize the eﬀects on primary
diabetic encephalopathy.
2. INSULIN AND C-PEPTIDE INTERACTIONS
After its discovery in the 1960s by Steiner [21–23], it was
believed that C-peptide, which plays an intricate part in
the biosynthesis and folding of insulin, would have an
insulin-like glucose lowering eﬀect. Since this turned out
not to be the case, C-peptide was abandoned and dismissed
as a nonfunctional peptide. However, in the 1990s, the
Karolinska group and others demonstrated eﬀects on blood
ﬂow, incipient diabetic nephropathy, and neuropathy in type
1 diabetic subjects [24–27]. This led to renewed interests in
the action of C-peptide. The Karolinska group demonstrated
speciﬁc binding of C-peptide to cell surfaces and suggested
that it acted via a G-protein-related receptor mechanism
[28]. Detailed studies by Grunberger et al. [19, 20, 29]
demonstrated that C-peptide autophosphorylates the insulin
receptor in the presence of insulin and stimulates p38 MAP-
kinase and PI-3 kinase activity and reduces the activation of
JNK phosphorylation, with subsequent dose-related eﬀects
on Na+/K+-ATPase activity and NO [30–32]. These experi-
ments seemed to suggest an insulinomimetic eﬀect,although
despite years of eﬀort by us and the Karolinska group,
we failed to identify a speciﬁc C-peptide receptor. Further
studies revealed an interesting stoichiometric relationship
between insulin and C-peptide pertaining to insulin signal-
ing activities. It was shown that in the presence of high
concentrations of insulin, C-peptide has an inhibitory eﬀect
on the combined insulin-signaling activity, whereas in the
presence of low insulin concentrations C-peptide enhances
insulin signaling [19, 20, 33]. Recent data have suggested
that the enhanced insulinomimetic eﬀect displayed by C-
peptide is due to its ability to dehexamerize insulin and
thereby enhance the intrinsic actions of insulin itself [34]. As
of yet unpublished data have demonstrated that the eﬀects
exerted by C-peptide on insulin action can be prolonged
by its binding of metal-ions such as chromium and iron.
It therefore appears that C-peptide interacts in a complex
way with insulin to produce its supporting insulinomimetic
eﬀects.
3. MECHANISMS UNDERLYING TYPE 1
AND TYPE 2 DPN
Theprogressiveevolutionofpathogeneticfactorsresponsible
for DPN can be divided into an early and reversible metabol-
ic phase and a partly overlapping progressively irreversible
structural phase [1, 35]( Figure 1).
An early metabolic perturbation is activation of the
polyol pathway by excessive glucose, resulting in accumula-
tionofsorbitolandfructoseanddepletionofotherosmolytes
such as taurin and myoinositol [36–38]. Myoinositol deple-
tion results in insuﬃcient diacylglycerol for Na+/K+-ATPase
activation [36]. The more severe Na+/K+-ATPase defect
in type 1 DPN is accounted for the additional defects
in protein kinase C activity caused by insulin and C-
peptide deﬁciencies [39]( Figure 1). Impaired endoneurial
blood ﬂow underlies endoneurial hypoxemia caused by
impaired eNOS expression and NO activity, abnormalities,
which are magniﬁed by insulin and C-peptide deﬁcien-
cies [32, 40, 41]( Figure 1). These aberrations have also
been associated with hyperglycemia-induced mitochondrial
dysfunction, overproduction of superoxide, oxidative, and
nitrosative stress [41, 42]. Such early reversible metabolic
abnormalities are associated with nerve conduction slowing,
which is signiﬁcantly more severe in type 1 BB/Wor-rats
than in their type 2 counterparts the BBZDR-rats [39, 43]
(Figure 2). These diﬀerences appear to be mainly due to
diﬀerences in the Na+/K+-ATPase defect [37, 39, 43, 44].
Since the excitation of the nodal membrane underlying the
propagation of nerve conduction depends on the inward
ﬂux of Na+, decreased Na+/K+-ATPase activity results in
improper inactivation of intra-axonal Na+ with decreased
permeabilityandintra-axonalNa+ accumulation,potentially
resulting in conduction block [45, 46].
Functional abnormalities of small nerve ﬁbers, partic-
ularly unmyelinated ﬁbers and small myelinated Aδ ﬁbers,
occur early and underlie hyperalgesia and allodynia or
neuropathic pain [48–50]( Figure 3). This is associatedAnders A. F. Sima et al. 3
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Figure 1: Scheme of pathogenetic events in type 1 (hyperglycemic and insulin and C-peptide deﬁcient) and type 2 (hyperglycemic)
BBZDR/Wor-rats. Insulin and C-peptide deﬁciencies add signiﬁcantly to early metabolic abnormalities such as Na+/K+-ATPase and NO
activities underlying the acute and reversible nerve conduction defect (dark gray). Subsequent changes with respect to gene regulatory
mechanisms and suppression of major neurotrophic factors and their receptors lead to severe axonal degeneration, atrophy, and loss; nodal
and paranodal degenerative changes; and impaired nerve ﬁber regeneration (dark gray). Such changes are responsible for the chronic and
increasingly irreversible nerve dysfunction, which are more severely expressed in type 1 diabetes. Mechanisms on which C-peptide has
preventive or corrective eﬀects are indicated with (∗).
with increased formation of Na+-channels and α-adrenergic
receptors resulting in hyperexcitability and ectopic dis-
charges in C-ﬁbers, which appears to be the initiating event
[51–54]. Other mechanisms which contribute to and sustain
pain are related to remodeling of large Aβ ﬁbers which form
collaterals with excitotoxic eﬀects on nociceptive spinal cord
neurons which amplify pain [54, 55]. Additional central
nervous system mechanisms involving noradrenalin and
serotonin reuptake as well as gabaergic eﬀects are involved
leading to diﬀerent levels of sensitization of pain. These
functionaldefectsoccurearlierandtoagreaterextentintype
1 DPN as compared to that of type 2 DPN [48]( Figure 3).
On the other hand, hyperalgesia appears to persist for a
longer period of time in type 2 diabetic rats (Figure 3),
which may explain the fact that nociceptive neuropathy is
more common in type 2 than in type 1 patients [56]. The
early damage to small peripheral nerve ﬁbers appears to
result from decreased neurotrophic support by insulin and
nerve growth factor (NGF) both of which are particularly
neurotrophic to small nociceptive ganglion cells [57, 58].
Impaired insulin and/or NGF support may also explain
the occurrence of painful diabetic neuropathy in prediabetic
patients with impaired insulin function [59, 60], and noci-
ceptive neuropathy in prediabetic rats with impaired glucose
tolerance but without overt hyperglycemic diabetes [61]. It
therefore appears that although hyperglycemia remains an
important factor in the pathogenesis of DPN, diﬀerences
in metabolic inﬂuences due to the presence or absence of
insulin action modulate the severity of DPN and is likely to
be the main explanation for the diﬀerences in DPN between
the two types of diabetes.
The structural and progressively irreversible DPN is
characterized by axonal atrophy and loss, which is more
severely expressed in type 1 as compared to type 2 DPN in
experimental diabetes [39, 43, 48] (Figures 1 and 4). Addi-
tional changes that characterize experimental and human
type 1 DPN is a progressive degenerative process aﬀecting
the paranodal and nodal apparati [4, 5, 16, 62]( Figure 5).
On the other hand, primary segmental degeneration is a
more common feature of type 2 human and experimental
diabetes, which may relate to abnormalities in caveolin-1
signaling, which in turn is modulated by cholesterol levels
[4, 5, 16, 39, 63].
Cytoskeletal neuroﬁlaments (NFs) and tubulins are
major constituents of the axon and their expression levels
and phosphorylation status determine axonal function and
size [64, 65]. Reduced expression of NFs and tubulins
occurs in experimental models of diabetes [66–69] and is
associated with decreased axonal transport of NFs [70, 71]
due to aberrant phosphorylation by phosphorylating protein
kinases [71–73]. NFs are unique to neurons and interact
with microtubules thereby forming the basis for axonal
transport. NFs consist of three intermediate ﬁlaments, NFL,
NFM, and NFH, forming coiled-coil dimers which align in4 Experimental Diabetes Research
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Figure 3: Longitudinal measurements of thermal hyperalgesia
in type 1 BB/Wor-rats without and with C-peptide replacement
from onset of diabetes compared to duration- and hyperglycemia-
matched type 2 BBZDR/Wor-rats and age-matched control rats.
Note more severe hyperalgesia in type 1 as compared to type 2 rats
and with partial but signiﬁcant prevention in C-peptide treated rats
[48, 49].
a staggered fashion. Several neurotrophic factors like NGF,
NT-3, IGF-1, insulin, and C-peptide stabilize NF transcripts
[14, 74, 75]. Aberrant phosphorylation of NFs perturbs their
function and interaction with other cytoskeletal components
resulting in malalignment of the cytoskeleton, impaired
axonal function, atrophy, and eventually loss [14, 76–78].
Several kinases are involved in NF phosphorylation such
as cyclin-dependent kinases including Cdk5 and the MAP
kinases Erk 1/2, SAPK [72], and GSKβ [79–81].
Tubulins assemble into microtubules and provide for
axonal transport and polarity [1]. Microtubule-associated
proteins like MAP1B and tau regulate their assembly [82–
84]. Inhibition of GSK-3β abolishes MAP1B phosphoryla-
tion which impacts on microtubule stability [85]. Reduced
expression of NFs and tubulins occur already in 2-mo
diabetic type 1 BB/Wor-rats and tend to progress with
duration of diabetes, whereas similar changes occur later and
are signiﬁcantly milder in type 2 BBZDR/Wor-rats [43, 66].
Simultaneously, neuroﬁlaments become hyperphosphory-
lated in type 1 diabetic rats via upregulation of phosphory-
lating stress kinases like SAPK and GSK-3β which emanate
from impaired insulin, IGF-1, and C-peptide signaling [86].
The structural consequences as would be expected, therefore
aﬀect type 1 DPN more severely than type 2 DPN with
unmyelinated ﬁbers being particularly vulnerable [16, 48]
(Figures 2, 3, 4,a n d6). A further diﬀerence between
type 1 and type 2 DPN occurs in sympathetic autonomic
nerves. STZ- and BB/Wor-rats develop dystrophic axonal
changes consisting of accumulations of NFs, tubolovesicular
conglomerates, and degenerated organelles. These changes
have been related to insulin and IGF-1 deﬁcits and do not
occur to a signiﬁcant degree in type 2 BBZDR/Wor-rats [87].
The diﬀerences in insulin-deﬁciency-mediated eﬀects on
neurotrophic factors and downstream deﬁcits in the expres-
sion and phosphorylation status of neuroskeletal proteins
also aﬀect the regenerative capacity of injured nerves. Hence,
the immediate gene responses following nerve injury and
upregulation of the expression of neuroskeletal, mRNAs, and
proteins are more severely perturbed in type 1 BB/Wor-rats
as compared to their type 2 counterpart, the BBZDR/Wor-
rats [43, 66, 69].
In recent years, it has been suggested by several investi-
gators [88, 89] that DPN is in part caused by mitochondrial
dysfunction-related apoptosis of dorsal root ganglion cells.
However, it is diﬃcult to reconcile this loss of DRG neurons
in the absence of peripheral sensory nerve ﬁber loss in
the streptozotocin diabetic rat. Although apoptotic stresses
do occur, more so in type 1 diabetic DRG cells than in
those of type 2 diabetes, these appear to be counteracted
by antiapoptotic mechanism [90, 91]. Instead the degener-
ation and eventually loss, particularly of small nociceptive
neurons, of DRGs in type 1 BB/Wor-rats appear to be due
to degeneration and vacuolation of the Golgi apparatus [92].
Probably the most intriguing diﬀerence encountered
in DPN in the two types of diabetes is the progressive
degeneration of the paranodal ion-channel barrier in type
1 DPN, which is unaﬀected in DPN accompanying type 2
diabetes [4, 5, 39, 62] (Figures 1 and 5). This abnormality
when ﬁrst described [4, 62] caused some controversy, since
it could not be identiﬁed in mostly type 2 diabetic nerve
[93–95]. The tight junctions which make up the paranodal
barrier are composed of cell adhesive molecules localized to
the axolemma such as casper, Na β-channels and contactin
and receptor protein tyrosin phosphatase β (RPTP-β)o n
the terminal loops of the myelin sheath (Figure 5). TheAnders A. F. Sima et al. 5
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Figure 4: Magnitudes of myelinated axon degeneration as assessed by teased ﬁber analysis (a) and ultrastructural quantiﬁcation of axoglial
dysjunction (b), a measure of paranodal degeneration. Note a signiﬁcantly more severe axonal degeneration in type 1 as compared to type 2
rats. C-peptide treatments from onset of diabetes and as an intervention between 5 and 8 months had signiﬁcant preventive and corrective
eﬀects on axonal degeneration. In (b) type 2 diabetes was not aﬀected by paranodal degeneration in contrast to type 1 diabetes showing
profound degeneration. C-peptide treatments had signiﬁcant preventive and therapeutic eﬀects on paranodal degeneration [17, 39, 47].
interaction of these adhesive molecules depends on their
posttranslational modiﬁcations, which become progressively
compromised in type 1 DPN, resulting in a breakup of
tight junctional structures and the barrier itself [62, 96–99].
Simultaneous defects in Na β-channels and ankyrinG of the
nodal axolemma dislodge the Na-α-channels which become
lateralized [97–99]( Figure 5). These abnormalities result in
decreased density of nodal Na-α-channels with profound
consequences as to the propagation of conduction impulses
[45, 62, 96–98]. Interestingly, the insulin receptor, which is
markedly downregulated in type 1 diabetes, colocalizes with
paranodal tight junctions and decorates the nodal axolemma
[100].
4. THE EFFECT OF C-PEPTIDE REPLACEMENT
ON TYPE 1 DPN
Initial in vitro studies on the eﬀect of C-peptide, demon-
strated insulin-like eﬀects [19, 20, 29, 101–105]. With regard
to DPN, we and several other groups demonstrated a dose-
related beneﬁcial eﬀect on neural Na+/K+-ATPase activity
[17, 31, 47], which constitutes the most important early
metabolic abnormality with consequences pertaining to
nerve conduction velocity as outlined above. Neurovascular
dysfunction associated with oxidative stress has emerged
as a contributing factor in the acute development of DPN
[42, 106–109].
C-peptidepromotesthereleaseofNOinendothelialcells
in a concentration-dependent manner [110]. In addition,
it increases the expression of eNOS protein and mRNA
which appears to be mediated via a MAP-kinase-dependent
mechanism [102, 110–112] .T h e s eo b s e r v a t i o n sa r ec o n s i s -
tent with in vivo ﬁndings in humans and animal models
[24, 25, 27, 32, 33, 113, 114].
The eﬀect of C-peptide replacement in type 1 BB/Wor-
rats, resulted in correction of endoneurial perfusion, the
nerve conduction defect, and attenuated thermal hyperal-
gesia [32]. It did not demonstrate an eﬀect on oxidative
stress. Inhibition of eNOS, but not of cyclooxygenase,
reversed the positive eﬀects of C-peptide [32]. Interestingly,
in hyperglycemia-matched type 2 BBZDR/Wor-rats, neu-
rovascular deﬁcits and increased oxidative stress were not
accompanied by nerve conduction slowing or hyperalgesia
[32]. These ﬁndings indicate that sensory nerve conduc-
tion deﬁcits and small ﬁber function are not inevitably
consequences of increased oxidative stress or decreased
endoneurial blood ﬂow in this type 2 rodent model
[32].
Insulin and C-peptide exert on their own neurotrophic
and antiapoptotic eﬀects [115–117]. In addition, C-peptide
has corrective eﬀects on the expression of several neu-
rotrophic factors such as NGF, IGF-1, and NT-3 and
their respective receptors [49, 50, 118]( Figure 7). These
regulatory eﬀects appear to be mediated by early gene6 Experimental Diabetes Research
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regulatory eﬀects of c-fos particularly on NGF as well as
by transcriptional factor NFκB with wider implications [66,
115]. The insulin receptor itself is in peripheral nerve located
primarily to the paranodal and nodal regions of myelinated
ﬁbers and to small nociceptive neurons in the DRGs [58,
100].
In the sciatic nerve, the expression of the insulin receptor
is upregulated in the BB/Wor-rat, whereas its expression in
type 2BBZDR/Wor-rats is downregulated bymore than50%
[66], in contrast the insulin receptor expression becomes
progressively downregulated in DRGs of the type 1 model
and remains unchanged in type 2 rats [48]. Systemic IGF-1
i sd e c r e a s e di nb o t hm o d e l s[ 3], whereas NGF and NF-3 are
impaired in sciatic nerves of the BB/Wor-rat but not in the
type 2 BBZDR/Wor-rat [48] and their respective receptors
are signiﬁcantly more severely aﬀected in the type 1 model
[48]. These aberrations in the expression of neurotrophic
factors and their receptors in the BB/Wor-rat are fully
prevented by full continuous substitution of C-peptide [49]
and are signiﬁcantly improved following intervention with
C-peptide [50]. Such beneﬁcial eﬀects on the neurotrophic
supporting network transcend into eﬀects on major neu-
roskeletal proteins such as NFs and neurotubulins [86, 118],
their postranslational modiﬁcations, and ultimately axonal
size, a major determinant of axonal function, hence resulting
in prevention and even reversal of nerve dysfunction [6,
17, 31, 49, 50] (Figures 2 and 3). As mentioned earlier,
nociceptive DRG neurons are speciﬁcally responsive to
insulin and NGF. It is therefore not totally surprising that
nociceptive nerve ﬁbers are particularly vulnerable to the
diabetic insult. In the type 1 model, they are more severely
aﬀected than in the type 2 rat [48] showing a progressive
axonal atrophy coupled with nociceptive neuronal atrophy
with ultimate C-ﬁber loss and loss of substance P and
calcitonin-gene-related neurons [49, 50]. The progressive
distalﬁberlossandsubsequentneuronalatrophyandlossare
not likely to reﬂect apoptotic cell death. Instead, apoptotic
stresses which indeed do occur are likely to be counteracted
by antiapoptotic elements such as heat shock proteins [119].
In a recent study, we demonstrated profound changes of the
Golgi apparatus particularly in small sensory DRG neurons
in the type 1 BB/Wor-rat and suggested that this may reﬂect
neurotrophic withdrawal with degeneration of cytoskeletal
binding proteins and microtubules [92].Anders A. F. Sima et al. 7
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Figure 7: Expression of the receptors of neurotrophic factors in dorsal root ganglia in 8-month type 1 diabetic (D1) and type 2 diabetic
(D2) rats, as well as type 1 rats replaced with C-peptide. (c) compared to age-matched control rats . Note marked decreases in the expression
of insulin receptor, IGF-1 receptor, and NGF-TrkA receptor in type 1 rats. These defects were signiﬁcantly milder in type 2 diabetic rats and
were signiﬁcantly prevented by C-peptide replacement in type 1 diabetic rats [50].
The impact of insulin-signaling on regulation of neu-
rotrophic support is also reﬂected by the eﬀect of C-peptide
on normalizing nerve ﬁber regeneration in the BB/Wor-rat
[118].
As mentioned above, one of the most characteristic
abnormalities occurring in type 1 human and experimental
diabetes is the progressive nodal and paranodal degeneration
[4,16,62].Axoglialdysjunctionisaprogressivedegeneration
of the paranodal ion-channel barrier which eventually
results in paranodal degeneration and reparative intercalated
internodes [4, 62]. This abnormality is not speciﬁc for type
1 DPN, but occurs in a series of clinical and experimental8 Experimental Diabetes Research
Table 1: Summary of the corrective eﬀects of C-peptide on
metabolic,molecular,functional,andstructuralparametersinDPN
and primary diabetic encephalopathy. Arrows indicate a decrease
(↓) or increase (↑) in the parameter in the non-C-peptide-treated
situation. The original ﬁndings are referenced.
Diabetic Neuropathy
Abnormality References
↓Na+/K+-ATPase [29, 88]
↓eNOS, NO [31, 95]
↓c-fos [63]
↓NFκB[ 84]
↓NGF, TrkA [49, 50, 98]
↓IGF-1, IGF-1R [49, 50, 98]
↓NT-3, TrkC [49, 50]
↓Insulin Receptor [49, 50]
↓Neuroﬁlaments [74, 98]
↓Tubulins [74, 98]
↓Substance P [49, 50]
↓CGRP [49, 50]
↓Cell adhesive molecules [82]
↑DRG neuronal atrophy [49, 50]
and loss
↓NCV [16, 29, 31, 49, 50, 74, 82, 88, 95]
↑Axonal atrophy and loss [16, 49, 50, 74, 88, 98]
↓Nerve ﬁber regeneration [98]
↑Axoglial dysjuction [16, 82, 88]
Primary Diabetic Encephalopathy
↓Insulin Receptor [96, 97, 104, 114, 115]
↓IGF-1, IGF-1R [97, 104, 114, 115]
↑Caspase 3 [114, 115]
↑Caspase 12 [114, 115]
↑Tau Unpublished data
↑Apoptosis [113, 115]
Cognitive function [114, 115]
neuropathies [120]. At the node, the voltage-gated Na+α-
channels are held in place by auxiliary subunits β1 and β2
Na-channels which act as adhesive molecules. Interaction
between contactin, ankyrinG,a n dβ-subunits are critical for
the enrichment and localization of Na+α-channels to the
nodal axolemma. AnkyrinG1 interacts with other nodal cell
adhesion molecules and its postranslational modiﬁcations
are important for these interactions. It interacts with the Na-
channel β-subunits which in turn interact with RPTP-β.
At the paranode, the myelin loops adhere to the axo-
lemma via tight junctions. Caspr is part of these and
interacts with contactin and RPTP-β. Caspr’s cytoplasmic
tail mediates protein-protein interaction through binding
with p85 at SH3 domains [99]. In myelinated nerve ﬁbers,
insulin receptors are particularly concentrated to the node
and the paranode [100]. In type 1 DPN, caspr and contactin
become signiﬁcantly downregulated together with RPTP-β
associated with a defect in caspr’s p85 binding. p85, the reg-
ulatory subunit of phosphatidyl-inositol 3-kinase, is possibly
mediated by insulin signaling (Figure 5). This sequence of
events leads to disruption of the tight junctions [99]. At the
node of Ranvier, the expression of Na+-channel α-subunits
is not altered, although the β1-subunit is downregulated
together with contactin and ankyrinG. In addition, the latter
undergoes O-linked N-acetylglucosylation, which inhibits
its phosphorylation and interaction with the Na-channel
β-units and contactin. This leads to dislodgement of Na-
channel α-subunits, which now migrate laterally through the
breached paranodal ion-channel barrier [97, 99].
C-peptide substitution in type 1 BB/Wor-rats prevents
the degenerative processes of the paranode and the node
of Ranvier [99] and intervention with C-peptide repairs the
paranodal apparatus as evidenced by an increased number
of intercalated internodes [17]. It therefore appears as if
these functionally signiﬁcant lesions in type 1 DPN relate to
abnormalities in insulin-signaling.
5. PRIMARY DIABETIC ENCEPHALOPATHY IN TYPE 1
DIABETES AND THE EFFECT OF C-PEPTIDE
Cognitive deﬁcits occur more commonly in diabetic patients
than in the nondiabetic population [121–125]. This is
probably in part due to ischemic pathologies due to cerebral
micro- and macrovascular disease, which may be con-
founded by hypertensive cerebral angiopathy or to repeated
episodes of severe hypoglycemia. Such conditions have been
referred to as secondary diabetic encephalopathy. However,
there is now growing evidence to suggest that cognitive
impairmentsmaybeconsequenttoperturbedmetabolismin
diabetes or so-called primary diabetic encephalopathy [126].
Impaired memory, problem solving ability, and intellectual
development have been documented in patients with type 1
diabetes. Such signs and symptoms have been accompanied
by electrophysiological and structural abnormalities [127–
130].Theseappeartobemorecommoninpatientswithearly
onset of diabetes and may in part relate to interference with
normal brain development [124, 131, 132].
Cognitive decline in patients with type 2 diabetes may
be associated with an increased risk for the development of
Alzheimer’s disease due to CNS insulin resistance and other
confounding factors, such as overweight and hypercholes-
terolemia [2, 122, 123].
Deﬁcitsincognitivefunctionhavealsobeendocumented
in experimental models of diabetes. In the streptozotocin-
induced diabetic rat, impaired cognitive performances have
been associated with abnormalities in hippocampal long-
term potentiation indicative of abnormal synaptic plasticity,
changes that are reversed by insulin treatment [133, 134].
We have demonstrated that impaired spatial memory in
diabetic BB/Wor-rats is preceded by signiﬁcant reductions in
the expression of IGF-1, IGF-II, IGF-1 receptor and insulin
receptor in hippocampus in 2 months diabetic rats [135].
These early ﬁndings were followed by increasingly impaired
deﬁcits in Morris water maze-testing, laddering of genomic
DNA in hippocampus and frontal cortex associated with
elevated Bax/Bcl-XL ratios, increased caspase 3 activity, and
neuronal loss in hippocampus [117, 135]. In these stud-
ies, full replacement with proinsulin C-peptide attenuated
the functional cognitive deﬁcits, normalized hippocampalAnders A. F. Sima et al. 9
expression of insulin and IGF-1 receptors, Bax expression,
and that of cleaved PARP, active caspase 3, and caspase 12.
These eﬀects were associated with signiﬁcant reductions in
hippocampal neuronal loss [117, 136].
On the other hand, in a recent study [3] of the type
2 BBZDR/Wor-rat, we demonstrated in the frontal cortex
perturbed amyloid precursor protein (APP) metabolism
with increased accumulation of β-amyloid, soluble APP, and
a 3-fold increase of Aβ C-terminal fragments. These changes
were associated with insulin resistance and decreased expres-
sion of insulin and IGF receptors and increased deposition
of phospho-tau. The consequence of these abnormalities
was decreased synapse density, neuritic degeneration, and
neuronalloss[2,3].Parallelstudiesinthetype1counterpart,
the BB/Wor-rat, showed similar changes although they were
signiﬁcantly milder as compared to type 2 rats [3]. Interest-
inglythough,amyloiddepositionandincreasedphospho-tau
were not aﬀected by C-peptide replacement (unpublished
data, Li and Sima).
It is therefore clear that cognitive deﬁcits occur in rodent
models of diabetes, which have not been genetically manip-
ulated. The underlying molecular abnormalities appear to
diﬀer in type 1 and type 2 diabetes. In the former, it appears
to be mainly caused by a deﬁcit in insulin signaling and
availability of neurotrophic support, which can be modiﬁed
by C-peptide replacement. In contrast, the rather profound
Alzheimer-like changes in type 2 diabetes appear to relate
to insulin-resistance and possibly elevated cholesterol levels,
abnormalities which do not appear to be responsive to C-
peptide treatment.
6. CONCLUDING THOUGHTS AND APPEALS
It is becoming increasingly evident that DPN diﬀers in the
two types of diabetes. This is not totally surprising when
considering the underlying pathophysiologic diﬀerences
betweentype1andtype2diabetes.Theonlycommonalityof
the two disorders is hyperglycemia. Although hyperglycemia
remains a prominent factor in the pathogenesis of the
chronic complications, probably equally important is the
role of insulin or lack thereof together with its prime
assistant C-peptide. Recognizing such diﬀerences will open
up areas of untapped therapeutic possibilities. One of these
concerns C-peptide. As outlined in this review, unlike
earlier examined therapeutic approaches which have met
with disappointing results, C-peptide corrects a number of
key pathogenetic mechanisms involved in DPN and has
experimentally and in limited clinical trials proven to be
highly eﬃcacious in preventing and even reversing DPN
in type 1 diabetes. In view of this, it is surprising that
major insulin manufacturing companies as well as main
granting agencies have approached this new evolving area
with such skepticism. The overriding concept is almost
embarrassingly simple: since the discovery of insulin and the
lack thereof in type 1 diabetes, we have for more than 80
years replaced it in type 1 patients and thereby saved millions
of lives, who however still develop the late complications
with signiﬁcant disabilities. Would not it now be about time
to also replace insulin’s companion and thereby prevent
millions of type 1 patients from developing the devastating
late complications? This concept takes on an even greater
dimension and urgency, when considering the preliminary
dataeludedtointhisreview,indicatingthepotentialeﬀectof
C-peptide substitution in preventing cognitive impairments
and even dementia in type 1 diabetic patients. Therefore,
we appeal to the pharmaceutical industry and federal and
private agencies to get involved. A great leap in the treatment
of type 1 diabetes may be just around the corner.
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